Introduction
The high mobility group box 1 protein (HMGB1) is a highly conserved and highly versatile nuclear and extracellular protein found in eukaryotic cells. HMGB1 is a non-histone, chromosomal protein that has been implicated in a variety of biologically important processes, including transcription, DNA repair, and extracellular signaling.
1 Structurally, HMGB1 consists of 215-amino acid polypeptide organized into two DNA-binding domains (termed A-box and B-box) and a negatively charged C-terminal tail. 2, 3 Functionally, HMGB1 appears to have two distinct roles in cellular systems. In the intracellular milieu, HMGB1 localizes to the nucleus and non-specifically binds to the minor groove of DNA, facilitates the assembly of DNA-binding proteins, and is involved in regulating gene transcription.
referred as an optimal marker of necrosis. 6, 7 It is involved in the mediation of neurite outgrowth, smooth muscle cell chemotaxis, mesoangioblast migration and proliferation, and tumor growth and metastasis. [8] [9] [10] The extracellular HMGB1 binds to several cell surface receptors, including the Receptor for Advanced Glycation End-products (RAGE) and the Triggering Receptor Expressed on Myeloid cells 1 (TREM-1).
11,12
RAGE is a transmembrane protein that belongs to the immunoglobulin superfamily. It can bind to advanced glycation end-products, the resulting product of nonenzymatic glycation. RAGE is mostly stimulated by cellular stress, such as inflammation and is therefore found to be overexpressed in many diseases, such as different cancers. 13 In certain cells, HMGB1 and its receptor, RAGE, co-localize on the cell surface. Authors have reported that HMGB1 binding to RAGE may activate signaling pathways, such as Ras/MAKP, PI3K/Akt, NF-kB, which leads to overexpression of genes and the change in the biological behavior of tumor cells. 14 Previous studies have found that HMGB1 and RAGE play important roles in the development, growth, and metastasis of multiple tumors.
15,16
The RAGE-HMGB1 interaction can diminish host anticancer immunity by inducing apoptosis in antigenpresenting dendritic cells and reprogram immune cells by promoting tumor-infiltrating T cell-expressed lymphotoxin a1b2, which leads to the recruitment of CD11b þ F4/ 80 þ macrophages (tumor-associated macrophages, TAMs)
into the tumor for its promotion (►Fig. 1) by providing growth factors and supporting angiogenesis. 17 Furthermore, HMGB1 released from necrotic cancer cells treated with chemotherapy enhances regrowth and metastasis of remnant cancer cells in a RAGE-dependent manner.
18,19
Therefore, blocking the HMGB1-RAGE system may increase the effectiveness of chemotherapy. 17 In fact, specialists have used soluble RAGE (sRAGE) to prevent the HMGB1-RAGE signaling from occurring in animal tumor models by acting as a decoy receptor. In comparison to RAGE, HMGB1 has been more extensively studied in various cancers. HMGB1 expression appears to be associated with many different tumor types. [21] [22] [23] [24] In addition, the association of HMGB1 overexpression and poor prognosis has been reported in patients with various types of cancers.
25-29
To our knowledge, however, a systematic evaluation of the clinical value of HMGB1 and RAGE in head and neck squamous cell carcinoma (HNSCC) has not been performed to date. HNSCC, which consists of several different subtypes, is the sixth most common malignancy in the world and the most common cause of cancer-related death in South Asia. 30 
Review of Literature
We performed a systematic search of the PubMed Database (through July 2015) of the National Library of Medicine using the following Medical Subject Headings: HMGB1 protein, advanced glycation end-product receptor, neoplasm, and head and neck neoplasms. The articles included discussed original research on the clinical value of HMGB1 or RAGE, including prognostic and diagnostic concordance, in head and neck neoplasms. We cross-referenced the search results with the Web of Science database, using the same terms. We excluded articles based on the following criteria: not written in English, conference abstract, and not performed on primary human subjects/specimens. An initial search of PubMed and Web of Science retrieved 421 articles (►Fig. 2). After reviewing titles and abstracts, excluding non-English articles and conference abstracts, 16 studies remained as potential candidates for inclusion. Full text review excluded five studies due to presentation of data irrelevant to the present topics. Ultimately, 11 studies were included in this systematic review, encompassing a total of 2,098 patients (►Table 1). Examination of HMGB1 and/or RAGE was predominantly performed in sectioned tissue, whether frozen (one study) or formalin-fixed and embedded in paraffin (7 studies). Four studies investigated expression levels in serum/blood. Studies in the squamous cell carcinoma (SCC) investigated the following malignancy types: general head and neck SCC (HNSCC, 2 studies), oral SCC (OSCC, 6 studies, including one study specifically on tongue SCC), nasopharyngeal carcinoma (2 studies), and SCC of the larynx (LSCC, 1 study). Of these, five studies indicated their included patients to be treatment naive. The study populations were between 50.0% and 96.3% male, with a mean/median age of 47.7 to 69.1 years.
The Receptor for Advanced Glycation End-products
Four studies evaluated RAGE in head and neck cancer patients [31] [32] [33] [34] (►Table 2). The earliest study to be included 31 analyzed samples from 20 patients with OSCC. The study compared expression of RAGE with angiogenesis and lymphangiogenesis, evaluated by microvessel density and lymph vessel density. A significant positive correlation was found between RAGE concentration and microvessel density (p ¼ 0.0123), but not between RAGE and lymph vessel density. Additionally, RAGE expression was significantly associated with concentration of vascular endothelial growth factor (VEGF; p ¼ 0.0344). The only clinic pathological factor to be significantly associated with RAGE expression was T-classification, with an elevated level seen inT3-T4 classifications compared with T1-T2 (p ¼ 0.0408).
In a study involving 38 OSCC cases, Landesberg et al 32 observed RAGE to be associated with tumor differentiation (p < 0.05). RAGE positivity was detected in 100% of welldifferentiated OSCC, 75% of well-to-moderately differentiated OSCC, 33% of moderately differentiated OSCC, 14% of moderate-to-poorly differentiated OSCC, and 0% of poorly differentiated OSCC. Additionally, RAGE expression trended toward decreasing staining intensity with less tumor differentiation.
The most recent and largest study 34 included 618 OSCC patients. Blood was collected and analyzed for RAGE gene polymorphism. Five polymorphisms of the RAGE gene were assessed: À374T > A (rs1800624), À429T > C (rs1800625), 1704G > T (rs184003), Gly82Ser (rs2070600), and a 63-bp deletion allele (À407 to À345). The heterozygous À429T > C genotype was found to be significantly associated with an increased incidence of oral cancer [odds ratio (OR), 
, and rs4540927. The 1177G > C polymorphism was associated with longer recurrence-free survival (p ¼ 0.000), but not overall survival (though a trend was noted of worse survival with the GG phenotype, p ¼ 0.104). Additionally, the 1177G > C variation was significantly associated higher histological nucleus grade (wild-type versus combined heterozygote and variant homozygote genotype, p ¼ 0.010), nodal metastasis (p ¼ 0.016), and higher clinical stage (p ¼ 0.030). Additionally, the 3814C > G variant was also significantly associated with nodal metastasis (wild-type versus combined heterozygote and variant homozygote genotype, p ¼ 0.019), and higher clinical stage (wild-type versus combined heterozygote and variant homozygote genotype, p ¼ 0.042).
One study analyzed the role of HMGB1 in 166 nasopharyngeal carcinoma specimens from treatment-naive patients. 37 found the subset of patients with both high HMGB1 expression and positive lymph node metastasis had an even poorer disease-free survival (p < 0.001) and overall survival (p < 0.001) than that of others.
Final Comments
The diagnostic value of HMGB1 in head and neck cancer, while not exhaustively investigated, may suffer from low sensitivity. No studies were found to evaluate the diagnostic value of RAGE. The demonstrated associations of HMGB1 and RAGE with clinic pathological characteristics of head and neck cancer patients offer a strong basis for further investigation into the prognostic value of both of these molecules. Early investigation has demonstrated HMGB1 to have definite potential as a predictor for survival, while RAGE has not been as extensively evaluated. Further studies are needed to confirm the clinical prognostic utility of both RAGE and HMGB1.
